IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Iradimed (NASDAQ: IRMD) announced that President and CEO Roger Susi and CFO Jack Glenn will attend the Goldman Sachs 47th Annual Global Healthcare Conference, held June 8–10, 2026, at the Loews Miami Beach Hotel in Miami Beach, Florida.
Interested investors can contact their Goldman Sachs representative to arrange one-on-one meetings with Iradimed management during the conference.
Positive
- None.
Negative
- None.
News Market Reaction – IRMD
In the May 20 session, IRMD gained 3.48%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 01 | Q1 2026 earnings | Positive | +4.5% | Reported Q1 2026 growth, record EPS, and reaffirmed full-year guidance. |
| Apr 27 | Earnings call notice | Neutral | +0.5% | Announced timing and access details for Q1 2026 results call. |
| Apr 10 | Needham conference | Neutral | -2.3% | Disclosed participation and one-on-one meetings at Needham virtual event. |
| Mar 16 | Roth conference | Neutral | +2.0% | Announced management one-on-one meetings at Roth investor conference. |
| Feb 10 | FY 2025 earnings | Positive | +9.6% | Reported record Q4 and full-year 2025 results plus dividend increase. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and guidance updates have drawn positive price reactions, while routine conference participation has produced mixed or counter-trend moves.
Over the last several months, IRADIMED has combined strong fundamentals with active investor outreach. Record Q4 2025 and solid Q1 2026 results, including revenue around $22M and rising EPS with a $0.20 quarterly dividend, were followed by multiple conference appearances and investor meetings. Earnings-related news on Feb 10 and May 1 produced gains of 9.57% and 4.45%, respectively, while conference participation headlines saw smaller, sometimes negative, moves. Today’s Goldman Sachs conference notice fits that ongoing outreach pattern.
Key Terms
mri-compatible medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida.
Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI") compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services. We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system specifically designed to be safe for use during MRI procedures. Our patented MRidium® MRI-compatible IV infusion pump systems and our 3880 MRI-compatible patient vital signs monitoring system are designed to enable accurate, safe, and dependable care before, during, and after MRI procedures. For more information, please visit www.iradimed.com.
For more information, please visit www.iradimed.com.
Media Contact:
Jack Glenn
Chief Financial Officer
Iradimed Corporation
(407) 677-8022
InvestorRelations@iradimed.com
